Hemophilia Management Market was worth USD 5.18 billion in 2015 and estimated to be growing at a CAGR of 1.62%, to reach USD 5.62 billion by 2017-2020.
The Global Hemophilia Management Market was worth USD 5.18 billion in 2015 and estimated to be growing at a CAGR of 1.62%, to reach USD 5.62 billion by 2020. Hemophilia is a genetic disorder which impairs body`s ability to control blood clotting.
Hemophilia usually occurs in males it is estimated that about 1 in 5000 males that are born each year contain hemophilia.
Full report at: www.marketdataforecast.com/market-…ement-market-310/
Hemophilia is categorized into three levels depending on its severity as severe, moderate and mild.
About 80% of the hemophilia patients are considered to suffer from severe type. The worldwide incidence of hemophilia is estimated at more than 400,000 people.
It is estimated that about 75% of the hemophilia patients do not receive adequate treatment.
Growing prevalence of the disease and increasing usage of recombinant product is expected to drive the market growth. Technological advancements and advancements in the novel coagulating factors and are also fuelling the growth of global Hemophilia Management market.
Rising investments in Research and developments for hemophilia products is also driving the market growth. However lack of available medication, awareness of this disease and high cost of treatment are the major restraining factors in the market.
Advancements in gene therapy and increasing number of drug approvals for treatment of hemophilia provide immense growth opportunities in the market.
Global Hemophilia management market is segmented on the basis of type of hemophilia and type of drug. By type of hemophilia it is further sub segmented into Hemophilia A and Hemophilia B.
Based on type of drug it is further sub segmented into Octocogalfa, Nonacogalfa, Desmopressin and other drugs. Hemophilia A is projected to have the highest growth rate driven by large number of patients suffering from hemophilia A
- BY Type
- By Drug
- Pfizer Inc.
- Baxter International Inc.
On the basis of geography Global hemophilia management market is analyzed under various regions namely North America, Europe, Asia-pacific, Latin America and Africa & Middle-East. North America is the largest market for hemophilia management accounting for approximately XX% due to high government support and the increasing number of patients suffering from hemophilia.
Europe is the second largest market for hemophilia management. Asia-Pacific region is estimated to be the fastest growing region owing to its high population base and increasing healthcare expenditure.
Latin America region provide lucrative opportunity for growth attributed to local government support and increasing focus of global players towards emerging economies.
Some of the major companies discussed in the report are Biogen, Baxter International Inc., Pfizer Inc., Bayer Pharma AG, Novo Nordisk A/S, Grifols International SA, CSL Behring, Octapharma and Swedish Orphan Biovitrum AB
Category: Market Research Publishers and RetailersCompany profile: Market Data Forecast is a firm working in the areas of market research, business intelligence and consulting. We have rich experience in research and consulting for various business domains to cater to the needs of both individual and corporate clients. A few key business areas that we handle with excellence include business process improvement, corporate financing and decision making based on market research, assisting in developing appropriate strategy and providing consultancy based on extens ...
For more information:Make an Inquiry about this report HERE!